US Uterine Fibroid Treatment Market Analysis:
U.S. Uterine Fibroid Treatment Market, By Procedure Type (Hysterectomy (Robotic Hysterectomy, Laparoscopic Hysterectomy, Vaginal Hysterectomy, Hysteroscopic Morcellation, Abdominal Hysterectomy), Endometrial Ablation, MRI Guided Procedures (MRI-guided Transcutaneous Focused Ultrasound, MRI-guided Percutaneous Laser Ablation), Myomectomy (Robotic Myomectomy, Laparoscopic Myomectomy, Open Myomectomy), Radiofrequency Ablation, Uterine Artery Embolization, Others), By End User (Hospitals, Ambulatory Surgical Centers) – Share, Outlook, Size, and Opportunity Analysis, 2020 – 2027
Uterine leiomyomas, commonly referred to as uterine fibroids, are the most frequently occurring tumors in the female reproductive system, causing disruption to the uterus and resulting in symptoms such as pelvic discomfort, anemia, and excessive bleeding. Several treatment options, including surgical procedures and drug therapy, are available for managing this condition.
The market for treating uterine fibroids in the United States was valued at US$ 243.5 million in 2020, and it is projected to increase to US$ 298.5 million by the end of 2027.
Ask Us to Get Your Sample Copy Of The Report, Covering TOC and Regional Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/3866
Drivers:
The U.S. market for uterine fibroids treatment is projected to experience growth in the projected timeframe due to a high prevalence of uterine fibroids among women. One example supporting this is a study published in October 2018 titled “A US population-based study of uterine fibroids diagnosis incidence, trends, and prevalence: 2005 through 2014,” which reported an incidence rate of 240.3 per 10,000 woman-years for fibroid diagnoses among women aged 45–49 in 2014.
In addition, the market is anticipated to benefit from the presence of efficient treatments. An example of such treatment is ulipristal acetate (UPA), which is capable of alleviating symptoms caused by uterine leiomyomata. UPA is sanctioned for usage in both the short-term, before surgery, and the long-term.
In 2019, the most prominent treatment for uterine fibroids in the United States was hysterectomy, which had a 79.0% share in terms of value. Myomectomy and endometrial ablation followed, in second and third place, respectively.
Restraints:
The anticipated hindrance to the growth of the uterine fibroid treatment market in the US arises from the complications linked with morcellators. Laparoscopic power morcellators, employed in myomectomy and hysterectomy procedures for the management of uterine fibroids, may lead to complications like metastatic leiomyosarcoma cancer.
The market’s growth is anticipated to be restricted by the costly and predominantly surgical nature of current fibroid treatments.
Opportunities:
Players in the market are anticipated to witness profitable growth prospects as a result of increased awareness and education related to the treatment of uterine fibroids. One example of this is the research paper titled ‘Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women’ published in November 2018, which revealed that women suffering from fibroids or exhibiting symptoms suggestive of fibroids encounter substantial distress, which impairs their quality of life. Moreover, a considerable number of women are probably undiagnosed, underscoring the necessity for enhanced awareness and education.
Despite being a challenging condition to investigate, there is a pressing need for thorough and inventive research on uterine fibroids due to the significant burden it imposes.
In 2019, the market for treating uterine fibroids in the United States was assessed at US$ 236.7 million, and it is estimated to attain US$ 298.5 million by 2027, growing at a compound annual growth rate (CAGR) of 3.0% during 2020–2027.
Market Trends:
The utilization of ulipristal acetate (UPA) can result in drug-induced liver damage, albeit a very uncommon idiosyncratic occurrence. Therefore, patients with liver abnormalities or disorders should avoid being prescribed UPA.
In the United States, pharmacologic therapy is widely used to treat uterine fibroids. According to a survey titled ‘Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women’, published in November 2018, 71% of patients with uterine fibroids relied on pharmacologic therapy for symptom relief, while 30% opted for surgical or procedural treatment.
Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/3866
Prominent companies:
Some of the prominent companies that are involved in providing treatment for uterine fibroids in the United States market are Myovant Sciences (Sumitovant Biopharma Ltd.), Boston Scientific Corporation, Merit Medical Systems, Blue Endo, Richard Wolf GmbH, CooperSurgical, Inc., Olympus Corporation, Halt Medical, Inc., KARL STORZ SE & Co. KG, and LiNA Medical USA.
Recent Developments:
Companies that hold significant market share are concentrating on research and development endeavors to broaden their range of products. As an example, Sumitovant Biopharma Ltd. disclosed the release of abstracts from Myovant Sciences in April 2020, which discussed the effectiveness and safety of relugolix combination therapy in treating heavy menstrual bleeding in women with uterine fibroids, published in the journal Obstetrics & Gynecology.
The market’s key participants are prioritizing the implementation of M&A tactics to broaden their range of products. As an example, CooperSurgical procured the assets of The LifeGlobal Group and its subsidiaries, which is a prominent worldwide supplier of in-vitro fertilization devices, in April 2018.
| The market size value in 2023 |
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐔𝐩 𝐓𝐨 𝟐𝟓% 𝐎𝐅𝐅 @ https://www.coherentmarketinsights.com/insight/buy-now/3866
Table of Contents with Major Points:
Executive Summary
- Introduction
- Key Findings
- Recommendations
- Definitions and Assumptions
Market Overview
- Definition of U.S. Uterine Fibroid Treatment Market
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Trends and Developments
Key Insights
- Key Emerging Trends
- Key Developments Mergers and Acquisition
- New Product Launches and Collaboration
- Partnership and Joint Venture
- Latest Technological Advancements
- Insights on Regulatory Scenario
- Porters Five Forces Analysis
Qualitative Insights Impact of COVID-19 on Global U.S. Uterine Fibroid Treatment Market
- Supply Chain Challenges
- Steps taken by Government/Companies to overcome this impact
- Potential opportunities due to COVID-19 outbreak
Conclusion
Appendix
- Data Sources
- Abbreviations
- Disclaimer
TOC Continued…!
Why Choose Coherent Market Insights?
☛ Identified business opportunities – Our market research report can be used to analyze potential markets and new products. It can give information about customer needs, preferences, and attitudes. Also, it compare products and services.
☛ A clear understanding of your customers – A market report gives company’s marketing department an in-depth picture about customers’ needs and wants. This knowledge can be used to improve products, prices, and advertising.
☛ Clear data-driven insights – Our Market research encompasses a wide range of activities, from determining market size and segment to forecasting demand, and from identifying competitors to monitoring pricing. All of these are quantified and measurable which means that gives you a clear path for building unique decisions based on numbers.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Mr Shah
Coherent Market Insights
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837